In the open-label part 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the primary time the mixture of cabozantinib, an anti-angiogenic agent, plus belzutifan, a first-in-class HIF-2? inhibitor. The findings are published in The Lancet Oncology journal.
The researchers beforehand reported outcomes for cohort 2 of the trial, which incorporates sufferers beforehand handled with immunotherapy. This study studies outcomes for cohort 1, which incorporates sufferers who haven’t but obtained remedy for superior kidney cancer.
After a median observe up of 24 months, 70% of sufferers had a confirmed goal response, with 4 of fifty sufferers experiencing an entire response and 31 of fifty experiencing a partial response. Seven of the 50 sufferers had critical treatment-related antagonistic occasions, although they had been manageable.
Current first-line remedy for superior clear-cell renal cell carcinoma consists of anti-PD1 or anti-PD-L1 immunotherapy together with a CTLA-4 inhibitor or a VEGF tyrosine kinase inhibitor resembling cabozantanib. These choices have improved outcomes in sufferers; nevertheless, not all sufferers reply, and a few responses don’t final. This study’s outcomes recommend that additional investigation of this novel mixture as first-line remedy choice is warranted.
More data:
Toni Ok Choueiri et al, Belzutifan plus cabozantinib as first-line remedy for sufferers with superior clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, part 2 study, The Lancet Oncology (2025). DOI: 10.1016/S1470-2045(24)00649-1
Citation:
Phase 2 outcomes recommend continued study of novel first-line combo for superior kidney cancer (2025, January 17)
18
phase-results-line-combo-advanced.html
.
. The content material is offered for data functions solely.